Robert Coleman, MD, FRCP

Today we speak with Dr. Robert Coleman about several new agents that have shown promise in early-stage clinical trials for ovarian cancer.

The magnitude of the role surgical exploration and extirpation play in the contemporary management of patients with advanced ovarian cancer is hard to overstate. Beyond diagnostic confirmation, the aggressive posture taken to remove bulk disease provides-among other benefits-symptomatic relief, theoretically enhanced immunologic integrity, chemosensitivity, and improved survival characteristics.

Bone is the most frequent andimportant site of metastaticcancer and is responsible foran enormous clinical burden and demandon health-care resources. Blumand colleagues comprehensively reviewthe management of bone metastases,argue for a more integratedcare pathway, and underscore the importanceof bone-specific treatmentsin reducing skeletal complications tomaintain quality of life and physicalfunctioning.